Mycobacterium Infections – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：273頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Mycobacterium Infections – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Mycobacterium Infections - Pipeline Review, H2 2012', provides an overview of the Mycobacterium Infections therapeutic pipeline. This report provides information on the therapeutic development for Mycobacterium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycobacterium Infections. 'Mycobacterium Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Mycobacterium Infections.
- A review of the Mycobacterium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mycobacterium Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Mycobacterium Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mycobacterium Infections pipeline depth and focus of Mycobacterium Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Mycobacterium Infections - Pipeline Review, H2 2012', provides an overview of the Mycobacterium Infections therapeutic pipeline. This report provides information on the therapeutic development for Mycobacterium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycobacterium Infections. 'Mycobacterium Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Mycobacterium Infections.
- A review of the Mycobacterium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mycobacterium Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Mycobacterium Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mycobacterium Infections pipeline depth and focus of Mycobacterium Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Mycobacterium Infections Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Mycobacterium Infections 11
Mycobacterium Infections Therapeutics under Development by Companies 13
Mycobacterium Infections Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Mycobacterium Infections Therapeutics – Products under Development by Companies 25
Mycobacterium Infections Therapeutics – Products under Investigation by Universities/Institutes 29
Companies Involved in Mycobacterium Infections Therapeutics Development 34
Johnson & Johnson 34
Sequella, Inc. 35
AlphaRx, Inc. 36
AstraZeneca PLC 37
GlaxoSmithKline plc 38
FASgen, Inc. 39
Emergent BioSolutions Inc. 40
Achillion Pharmaceuticals, Inc. 41
Pfizer Inc. 42
Vertex Pharmaceuticals Incorporated 43
AVI BioPharma Inc. 44
Crucell N.V. 45
Insmed Incorporated 46
Intercell AG 47
Lupin Limited 48
Albert Einstein College of Medicine of Yeshiva University 49
Summit Corporation plc 50
PolyMedix, Inc. 51
Immune Network Research Ltd. 52
Snowdon Inc. 53
ImmunoBiology Limited 54
Recipharm AB 55
Telormedix SA 56
ApoImmune, Inc. 57
Mondobiotech Holding AG 58
EpiVax, Inc. 59
Archivel Farma S.L. 60
Canopus BioPharma Incorporated 61
Avir Green Hills Biotechnology AG 62
TVAX Biomedical, LLC 63
Medisyn Technologies, Inc. 64
Vakzine Projekt Management GmbH 65
ISA Pharmaceuticals B.V. 66
Lipotek Pty Ltd 67
Mycobacterium Infections – Therapeutics Assessment 68
Assessment by Monotherapy Products 68
Assessment by Combination Products 69
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
OPC-67683 - Drug Profile 74
Streptomycin NDS - Drug Profile 75
Arikace - Drug Profile 76
SND-159 - Drug Profile 78
PMX-10072 - Drug Profile 79
TMC 207 - Drug Profile 80
SQ-109 - Drug Profile 82
MVA85A - Drug Profile 84
Vaccine For Tuberculosis - Drug Profile 87
ApoVax104-TB Vaccine - Drug Profile 88
Rifalazil - Drug Profile 89
SQ-609 - Drug Profile 91
NasL3/HtkBCG - Drug Profile 93
rBCG T+B rM. Smegmatis T+B - Drug Profile 94
MTBVAC01 - Drug Profile 95
FAS20013 - Drug Profile 96
PNU-100480 - Drug Profile 97
VPM1002 - Drug Profile 98
HG85 A/B - Drug Profile 99
HG856A - Drug Profile 100
VecFlu - Drug Profile 101
PS-Conjugate Vaccine - Drug Profile 102
BCG Danish Attenuated Recombinant Live Vaccine - Drug Profile 103
GSK692342 - Drug Profile 104
R32kDa BCG Protein - Drug Profile 106
r30 - Drug Profile 107
TB Vaccine - Drug Profile 108
Linezolid - Drug Profile 109
Isoniazid - Drug Profile 110
TB Proteasome Inhibitor Program - Drug Profile 111
HBHA - Drug Profile 112
Streptomyces Live Vector - Drug Profile 113
rBCG(mbtB)30 - Drug Profile 114
LL 3858 - Drug Profile 115
Rifapentine - Drug Profile 116
Ad5Ag85A - Drug Profile 117
Metronidazole - Drug Profile 118
Isoniazid + Cotrimoxazole - Drug Profile 120
Drug For Tuberculosis - Drug Profile 121
Moxifloxacin + Rifapentine - Drug Profile 122
Ciclosporin - Drug Profile 124
Emtricitabine + Tenofovir + Efavirenz - Drug Profile 125
Rifapentine - Drug Profile 127
Rifampicin - Drug Profile 128
Isoniazid + Rifapentine - Drug Profile 129
Crucell Ad35 - Drug Profile 131
RUTI - Drug Profile 133
FP85A - Drug Profile 134
FP85A + MVA85A - Drug Profile 135
Ag85B-ESAT-6 + CAF01 - Drug Profile 136
Perforin 2 - Drug Profile 137
L-Arginine + Cholecalciferol - Drug Profile 138
Alpha-1 Antitrypsin - Drug Profile 140
Isoniazid - Drug Profile 142
Rifampin - Drug Profile 143
Prednisone - Drug Profile 144
Rifabutin + Efavirenz - Drug Profile 145
Rifabutin + Nevirapine - Drug Profile 146
Rifabutin + Lopinavir + Ritonavir - Drug Profile 147
Isoniazid - Drug Profile 149
Rifampin - Drug Profile 150
Ag85B-ESAT-6 Vaccine - Drug Profile 151
SQ-109 + bedaquiline - Drug Profile 153
Clarithromycin + Ethambutol + Rifabutin - Drug Profile 154
Clarithromycin + Ethambutol + Clofazimine - Drug Profile 155
AZD5847 - Drug Profile 157
Zyvox - Drug Profile 158
Recombinant Tuberculosis Vaccine - Drug Profile 159
Amithiozone + Clarithromycin + Ethambutol + Rifampin + Streptomycin - Drug Profile 160
Actimmune + Leukine - Drug Profile 162
Nevirapine + Rifampicin + Ethambutol + Isoniazid + Pyrazinamid - Drug Profile 163
PA-824 - Drug Profile 165
Lopinavir + Ritonavir + NRTIs + Rifampicin - Drug Profile 166
Moxifloxacin + Isoniazid + Rifampicin + Pyrazinamide + Ethambutol - Drug Profile 168
Vaccine For Tuberculosis - Drug Profile 170
Rifampicin - Drug Profile 171
BCG Intradermal + BCG Oral - Drug Profile 172
RUTI + Isoniazid - Drug Profile 173
Cholecalciferol - Drug Profile 174
PA-824 + Pyrazinamide + Moxifloxacin - Drug Profile 175
Moxifloxacin - Drug Profile 176
SQ109 + Rifampicin - Drug Profile 177
V-5 Immunitor - Drug Profile 178
PA-824 + Pyrzinamide - Drug Profile 180
TMC207 + Pyrazinamide - Drug Profile 181
Moxifloxacin + Isoniazid + Rifampicin + Pyrazinamide + Ethambutol - Drug Profile 182
NasL3/AM85B - Drug Profile 184
Moxifloxacin - Drug Profile 185
paBCG Vaccine - Drug Profile 186
Mycobacterium vaccae - Drug Profile 187
AERAS-422 - Drug Profile 188
RNTCP Category I Regimen - Drug Profile 189
GSK M72 - Drug Profile 191
Rifalazil + Isoniazid - Drug Profile 192
N-Acetyl Cysteine - Drug Profile 193
Drug For Tuberculosis - Drug Profile 194
FP6 TBVAC - Drug Profile 195
SSI HyVac4 - Drug Profile 196
ORT-VAC DNA Vaccine - Drug Profile 197
DasKloster 0249-01 - Drug Profile 198
Clarithromycin - Drug Profile 199
Moxifloxacin - Drug Profile 200
Antibacterial Program - Drug Profile 201
TMX-201 - Drug Profile 202
PMX-10070 - Drug Profile 203
PMX30053 - Drug Profile 204
TB-SLP - Drug Profile 205
RHB-104 - Drug Profile 206
RHB-104 - Drug Profile 208
MTbuVax - Drug Profile 210
SSI H56-IC31 - Drug Profile 211
SSI/SP H4-IC31 - Drug Profile 212
MicroRNA-Like Molecules - Drug Profile 214
TVI-Tuberculosis-1 - Drug Profile 215
ID93/GLA-SE - Drug Profile 216
Tuberculosis Program - Drug Profile 217
ALX-09 - Drug Profile 219
IMX-461 - Drug Profile 220
V7 Vaccine - Drug Profile 221
Human Liporale - BCG Vaccine - Drug Profile 223
IKEPLUS - Drug Profile 224
rhPIV2-Ag85B - Drug Profile 225
BCG Vaccine - Drug Profile 226
rBCG85C - Drug Profile 227
Anti-Tubercular Program - Drug Profile 228
Mycobacterium Habana Vaccine - Drug Profile 229
Mycobacterium Infections Therapeutics – Drug Profile Updates 231
Mycobacterium Infections Therapeutics – Discontinued Products 246
Mycobacterium Infections Therapeutics - Dormant Products 247
Mycobacterium Infections – Product Development Milestones 252
Featured News & Press Releases 252
Appendix 263
Methodology 263
Coverage 263
Secondary Research 263
Primary Research 263
Expert Panel Validation 263
Contact Us 264
Disclaimer 264
List of Tables
Number of Products Under Development for Mycobacterium Infections, H2 2012 20
Products under Development for Mycobacterium Infections – Comparative Analysis, H2 2012 21
Number of Products under Development by Companies, H2 2012 23
Number of Products under Development by Companies, H2 2012 (Contd..1) 24
Number of Products under Development by Companies, H2 2012 (Contd..2) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 29
Comparative Analysis by Late Stage Development, H2 2012 30
Comparative Analysis by Mid Clinical Stage Development, H2 2012 31
Comparative Analysis by Early Clinical Stage Development, H2 2012 32
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Development by Companies, H2 2012 (Contd..1) 35
Products under Development by Companies, H2 2012 (Contd..2) 36
Products under Development by Companies, H2 2012 (Contd..3) 37
Products under Investigation by Universities/Institutes, H2 2012 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 40
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 42
Johnson & Johnson, H2 2012 43
Sequella, Inc., H2 2012 44
AlphaRx, Inc., H2 2012 45
AstraZeneca PLC, H2 2012 46
GlaxoSmithKline plc, H2 2012 47
FASgen, Inc., H2 2012 48
Emergent BioSolutions Inc., H2 2012 49
Achillion Pharmaceuticals, Inc., H2 2012 50
Pfizer Inc., H2 2012 51
Vertex Pharmaceuticals Incorporated, H2 2012 52
AVI BioPharma Inc., H2 2012 53
Crucell N.V., H2 2012 54
Insmed Incorporated, H2 2012 55
Intercell AG, H2 2012 56
Lupin Limited, H2 2012 57
Albert Einstein College of Medicine of Yeshiva University, H2 2012 58
Summit Corporation plc, H2 2012 59
PolyMedix, Inc., H2 2012 60
Immune Network Research Ltd., H2 2012 61
Snowdon Inc., H2 2012 62
ImmunoBiology Limited, H2 2012 63
Recipharm AB, H2 2012 64
Telormedix SA, H2 2012 65
ApoImmune, Inc., H2 2012 66
Mondobiotech Holding AG, H2 2012 67
EpiVax, Inc., H2 2012 68
Archivel Farma S.L., H2 2012 69
Canopus BioPharma Incorporated, H2 2012 70
Avir Green Hills Biotechnology AG, H2 2012 71
TVAX Biomedical, LLC, H2 2012 72
Medisyn Technologies, Inc., H2 2012 73
Vakzine Projekt Management GmbH, H2 2012 74
ISA Pharmaceuticals B.V., H2 2012 75
Lipotek Pty Ltd, H2 2012 76
Assessment by Monotherapy Products, H2 2012 77
Assessment by Combination Products, H2 2012 78
Assessment by Stage and Route of Administration, H2 2012 80
Assessment by Stage and Molecule Type, H2 2012 82
Mycobacterium Infections Therapeutics – Drug Profile Updates 240
Mycobacterium Infections Therapeutics – Discontinued Products 255
Mycobacterium Infections Therapeutics – Dormant Products 256
Mycobacterium Infections Therapeutics – Dormant Products (Contd..1) 257
Mycobacterium Infections Therapeutics – Dormant Products (Contd..2) 258
Mycobacterium Infections Therapeutics – Dormant Products (Contd..3) 259
Mycobacterium Infections Therapeutics – Dormant Products (Contd..4) 260
List of Figures
Number of Products under Development for Mycobacterium Infections, H2 2012 20
Products under Development for Mycobacterium Infections – Comparative Analysis, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 26
Late Stage Products, H2 2012 30
Mid Clinical Stage Products, H2 2012 31
Early Clinical Stage Products, H2 2012 32
Discovery and Pre-Clinical Stage Products, H2 2012 33
Assessment by Monotherapy Products, H2 2012 77
Assessment by Combination Products, H2 2012 78
Assessment by Route of Administration, H2 2012 79
Assessment by Stage and Route of Administration, H2 2012 80
Assessment by Molecule Type, H2 2012 81
Assessment by Stage and Molecule Type, H2 2012 82
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Mycobacterium Infections Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Mycobacterium Infections 11
Mycobacterium Infections Therapeutics under Development by Companies 13
Mycobacterium Infections Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Mycobacterium Infections Therapeutics – Products under Development by Companies 25
Mycobacterium Infections Therapeutics – Products under Investigation by Universities/Institutes 29
Companies Involved in Mycobacterium Infections Therapeutics Development 34
Johnson & Johnson 34
Sequella, Inc. 35
AlphaRx, Inc. 36
AstraZeneca PLC 37
GlaxoSmithKline plc 38
FASgen, Inc. 39
Emergent BioSolutions Inc. 40
Achillion Pharmaceuticals, Inc. 41
Pfizer Inc. 42
Vertex Pharmaceuticals Incorporated 43
AVI BioPharma Inc. 44
Crucell N.V. 45
Insmed Incorporated 46
Intercell AG 47
Lupin Limited 48
Albert Einstein College of Medicine of Yeshiva University 49
Summit Corporation plc 50
PolyMedix, Inc. 51
Immune Network Research Ltd. 52
Snowdon Inc. 53
ImmunoBiology Limited 54
Recipharm AB 55
Telormedix SA 56
ApoImmune, Inc. 57
Mondobiotech Holding AG 58
EpiVax, Inc. 59
Archivel Farma S.L. 60
Canopus BioPharma Incorporated 61
Avir Green Hills Biotechnology AG 62
TVAX Biomedical, LLC 63
Medisyn Technologies, Inc. 64
Vakzine Projekt Management GmbH 65
ISA Pharmaceuticals B.V. 66
Lipotek Pty Ltd 67
Mycobacterium Infections – Therapeutics Assessment 68
Assessment by Monotherapy Products 68
Assessment by Combination Products 69
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
OPC-67683 - Drug Profile 74
Streptomycin NDS - Drug Profile 75
Arikace - Drug Profile 76
SND-159 - Drug Profile 78
PMX-10072 - Drug Profile 79
TMC 207 - Drug Profile 80
SQ-109 - Drug Profile 82
MVA85A - Drug Profile 84
Vaccine For Tuberculosis - Drug Profile 87
ApoVax104-TB Vaccine - Drug Profile 88
Rifalazil - Drug Profile 89
SQ-609 - Drug Profile 91
NasL3/HtkBCG - Drug Profile 93
rBCG T+B rM. Smegmatis T+B - Drug Profile 94
MTBVAC01 - Drug Profile 95
FAS20013 - Drug Profile 96
PNU-100480 - Drug Profile 97
VPM1002 - Drug Profile 98
HG85 A/B - Drug Profile 99
HG856A - Drug Profile 100
VecFlu - Drug Profile 101
PS-Conjugate Vaccine - Drug Profile 102
BCG Danish Attenuated Recombinant Live Vaccine - Drug Profile 103
GSK692342 - Drug Profile 104
R32kDa BCG Protein - Drug Profile 106
r30 - Drug Profile 107
TB Vaccine - Drug Profile 108
Linezolid - Drug Profile 109
Isoniazid - Drug Profile 110
TB Proteasome Inhibitor Program - Drug Profile 111
HBHA - Drug Profile 112
Streptomyces Live Vector - Drug Profile 113
rBCG(mbtB)30 - Drug Profile 114
LL 3858 - Drug Profile 115
Rifapentine - Drug Profile 116
Ad5Ag85A - Drug Profile 117
Metronidazole - Drug Profile 118
Isoniazid + Cotrimoxazole - Drug Profile 120
Drug For Tuberculosis - Drug Profile 121
Moxifloxacin + Rifapentine - Drug Profile 122
Ciclosporin - Drug Profile 124
Emtricitabine + Tenofovir + Efavirenz - Drug Profile 125
Rifapentine - Drug Profile 127
Rifampicin - Drug Profile 128
Isoniazid + Rifapentine - Drug Profile 129
Crucell Ad35 - Drug Profile 131
RUTI - Drug Profile 133
FP85A - Drug Profile 134
FP85A + MVA85A - Drug Profile 135
Ag85B-ESAT-6 + CAF01 - Drug Profile 136
Perforin 2 - Drug Profile 137
L-Arginine + Cholecalciferol - Drug Profile 138
Alpha-1 Antitrypsin - Drug Profile 140
Isoniazid - Drug Profile 142
Rifampin - Drug Profile 143
Prednisone - Drug Profile 144
Rifabutin + Efavirenz - Drug Profile 145
Rifabutin + Nevirapine - Drug Profile 146
Rifabutin + Lopinavir + Ritonavir - Drug Profile 147
Isoniazid - Drug Profile 149
Rifampin - Drug Profile 150
Ag85B-ESAT-6 Vaccine - Drug Profile 151
SQ-109 + bedaquiline - Drug Profile 153
Clarithromycin + Ethambutol + Rifabutin - Drug Profile 154
Clarithromycin + Ethambutol + Clofazimine - Drug Profile 155
AZD5847 - Drug Profile 157
Zyvox - Drug Profile 158
Recombinant Tuberculosis Vaccine - Drug Profile 159
Amithiozone + Clarithromycin + Ethambutol + Rifampin + Streptomycin - Drug Profile 160
Actimmune + Leukine - Drug Profile 162
Nevirapine + Rifampicin + Ethambutol + Isoniazid + Pyrazinamid - Drug Profile 163
PA-824 - Drug Profile 165
Lopinavir + Ritonavir + NRTIs + Rifampicin - Drug Profile 166
Moxifloxacin + Isoniazid + Rifampicin + Pyrazinamide + Ethambutol - Drug Profile 168
Vaccine For Tuberculosis - Drug Profile 170
Rifampicin - Drug Profile 171
BCG Intradermal + BCG Oral - Drug Profile 172
RUTI + Isoniazid - Drug Profile 173
Cholecalciferol - Drug Profile 174
PA-824 + Pyrazinamide + Moxifloxacin - Drug Profile 175
Moxifloxacin - Drug Profile 176
SQ109 + Rifampicin - Drug Profile 177
V-5 Immunitor - Drug Profile 178
PA-824 + Pyrzinamide - Drug Profile 180
TMC207 + Pyrazinamide - Drug Profile 181
Moxifloxacin + Isoniazid + Rifampicin + Pyrazinamide + Ethambutol - Drug Profile 182
NasL3/AM85B - Drug Profile 184
Moxifloxacin - Drug Profile 185
paBCG Vaccine - Drug Profile 186
Mycobacterium vaccae - Drug Profile 187
AERAS-422 - Drug Profile 188
RNTCP Category I Regimen - Drug Profile 189
GSK M72 - Drug Profile 191
Rifalazil + Isoniazid - Drug Profile 192
N-Acetyl Cysteine - Drug Profile 193
Drug For Tuberculosis - Drug Profile 194
FP6 TBVAC - Drug Profile 195
SSI HyVac4 - Drug Profile 196
ORT-VAC DNA Vaccine - Drug Profile 197
DasKloster 0249-01 - Drug Profile 198
Clarithromycin - Drug Profile 199
Moxifloxacin - Drug Profile 200
Antibacterial Program - Drug Profile 201
TMX-201 - Drug Profile 202
PMX-10070 - Drug Profile 203
PMX30053 - Drug Profile 204
TB-SLP - Drug Profile 205
RHB-104 - Drug Profile 206
RHB-104 - Drug Profile 208
MTbuVax - Drug Profile 210
SSI H56-IC31 - Drug Profile 211
SSI/SP H4-IC31 - Drug Profile 212
MicroRNA-Like Molecules - Drug Profile 214
TVI-Tuberculosis-1 - Drug Profile 215
ID93/GLA-SE - Drug Profile 216
Tuberculosis Program - Drug Profile 217
ALX-09 - Drug Profile 219
IMX-461 - Drug Profile 220
V7 Vaccine - Drug Profile 221
Human Liporale - BCG Vaccine - Drug Profile 223
IKEPLUS - Drug Profile 224
rhPIV2-Ag85B - Drug Profile 225
BCG Vaccine - Drug Profile 226
rBCG85C - Drug Profile 227
Anti-Tubercular Program - Drug Profile 228
Mycobacterium Habana Vaccine - Drug Profile 229
Mycobacterium Infections Therapeutics – Drug Profile Updates 231
Mycobacterium Infections Therapeutics – Discontinued Products 246
Mycobacterium Infections Therapeutics - Dormant Products 247
Mycobacterium Infections – Product Development Milestones 252
Featured News & Press Releases 252
Appendix 263
Methodology 263
Coverage 263
Secondary Research 263
Primary Research 263
Expert Panel Validation 263
Contact Us 264
Disclaimer 264
List of Tables
Number of Products Under Development for Mycobacterium Infections, H2 2012 20
Products under Development for Mycobacterium Infections – Comparative Analysis, H2 2012 21
Number of Products under Development by Companies, H2 2012 23
Number of Products under Development by Companies, H2 2012 (Contd..1) 24
Number of Products under Development by Companies, H2 2012 (Contd..2) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 29
Comparative Analysis by Late Stage Development, H2 2012 30
Comparative Analysis by Mid Clinical Stage Development, H2 2012 31
Comparative Analysis by Early Clinical Stage Development, H2 2012 32
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Development by Companies, H2 2012 (Contd..1) 35
Products under Development by Companies, H2 2012 (Contd..2) 36
Products under Development by Companies, H2 2012 (Contd..3) 37
Products under Investigation by Universities/Institutes, H2 2012 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 40
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 42
Johnson & Johnson, H2 2012 43
Sequella, Inc., H2 2012 44
AlphaRx, Inc., H2 2012 45
AstraZeneca PLC, H2 2012 46
GlaxoSmithKline plc, H2 2012 47
FASgen, Inc., H2 2012 48
Emergent BioSolutions Inc., H2 2012 49
Achillion Pharmaceuticals, Inc., H2 2012 50
Pfizer Inc., H2 2012 51
Vertex Pharmaceuticals Incorporated, H2 2012 52
AVI BioPharma Inc., H2 2012 53
Crucell N.V., H2 2012 54
Insmed Incorporated, H2 2012 55
Intercell AG, H2 2012 56
Lupin Limited, H2 2012 57
Albert Einstein College of Medicine of Yeshiva University, H2 2012 58
Summit Corporation plc, H2 2012 59
PolyMedix, Inc., H2 2012 60
Immune Network Research Ltd., H2 2012 61
Snowdon Inc., H2 2012 62
ImmunoBiology Limited, H2 2012 63
Recipharm AB, H2 2012 64
Telormedix SA, H2 2012 65
ApoImmune, Inc., H2 2012 66
Mondobiotech Holding AG, H2 2012 67
EpiVax, Inc., H2 2012 68
Archivel Farma S.L., H2 2012 69
Canopus BioPharma Incorporated, H2 2012 70
Avir Green Hills Biotechnology AG, H2 2012 71
TVAX Biomedical, LLC, H2 2012 72
Medisyn Technologies, Inc., H2 2012 73
Vakzine Projekt Management GmbH, H2 2012 74
ISA Pharmaceuticals B.V., H2 2012 75
Lipotek Pty Ltd, H2 2012 76
Assessment by Monotherapy Products, H2 2012 77
Assessment by Combination Products, H2 2012 78
Assessment by Stage and Route of Administration, H2 2012 80
Assessment by Stage and Molecule Type, H2 2012 82
Mycobacterium Infections Therapeutics – Drug Profile Updates 240
Mycobacterium Infections Therapeutics – Discontinued Products 255
Mycobacterium Infections Therapeutics – Dormant Products 256
Mycobacterium Infections Therapeutics – Dormant Products (Contd..1) 257
Mycobacterium Infections Therapeutics – Dormant Products (Contd..2) 258
Mycobacterium Infections Therapeutics – Dormant Products (Contd..3) 259
Mycobacterium Infections Therapeutics – Dormant Products (Contd..4) 260
List of Figures
Number of Products under Development for Mycobacterium Infections, H2 2012 20
Products under Development for Mycobacterium Infections – Comparative Analysis, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 26
Late Stage Products, H2 2012 30
Mid Clinical Stage Products, H2 2012 31
Early Clinical Stage Products, H2 2012 32
Discovery and Pre-Clinical Stage Products, H2 2012 33
Assessment by Monotherapy Products, H2 2012 77
Assessment by Combination Products, H2 2012 78
Assessment by Route of Administration, H2 2012 79
Assessment by Stage and Route of Administration, H2 2012 80
Assessment by Molecule Type, H2 2012 81
Assessment by Stage and Molecule Type, H2 2012 82
